Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Ocular Therapeutix in a report on Wednesday, October 4th. View […]
StockNews.com cut shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) from a hold rating to a sell rating in a research report sent to investors on Sunday. Several other research analysts have also recently issued reports on the stock. Robert W. Baird restated an outperform rating and issued a $18.00 target price on shares of […]
StockNews.com downgraded shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) from a hold rating to a sell rating in a research note published on Friday. A number of other analysts have also recently commented on the stock. HC Wainwright restated a buy rating and issued a $12.00 price objective on shares of Ocular Therapeutix in […]
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday. A number of other brokerages have also commented on OCUL. Robert W. Baird reaffirmed an “outperform” rating and set a $18.00 target price on shares of […]
Robert W. Baird reiterated their outperform rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note released on Thursday, Benzinga reports. Robert W. Baird currently has a $18.00 price target on the biopharmaceutical company’s stock. Other analysts have also issued reports about the stock. HC Wainwright restated a buy rating and […]